|

Rituximab (R) Clinical Trials

5 actively recruiting trials across 1 location

Also known as: Induction phase, Rituximab

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Ruijin Hospital2
  • The Lymphoma Academic Research Organisation1
  • Institute of Hematology & Blood Diseases Hospital, China1
  • InnoCare Pharma Inc.1

Indications

  • Cancer5
  • Mantle Cell Lymphoma (MCL)2
  • Mature B-cell Malignancies1
  • Diffuse Large B-Cell Lymphoma1
  • Marginal Zone Lymphoma1

Other4 trials

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase 3
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Phase 2
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Phase 2
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Phase 1/2

Plantation, Florida1 trial

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

BRCR Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.